- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA advisory panel to consider OTC status of NSAIDs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Senate passes Drug Quality and Security Act
FRANKLIN LAKES, N.J. — The Food and Drug Administration has approved a second product in BD's new line of injectable drugs, the company said Tuesday.
BD Rx, the pharmaceutical arm of the medical technology manufacturer, whose name stands for Becton, Dickinson and Co., received FDA approval for metoclopramide, part of its BD Simplist line of ready-to-administer pre-filled generic injectables. The product is an antiemetic, a drug used to stop vomiting.
The company previously launched BD Simplist diphenhydramine hydrochloride injection, an antihistamine, last month. The company plans to launch 20 to 30 products in the line over the next few years.
"After a successful launch of BD Simplist pre-filled injectables, we're excited to be coming out with a second drug that is commonly used by clinicians," BD Rx president Mark Sebree said. "This is just the beginning of our new line of pre-filled injectable products."
The company said that every injection carries the potential for medication error, but while traditional vial and syringe injections, clinicians perform up to 20 steps; with the BD Simplist syringes, the sequence is reduced to about 12 steps.